On November 28, the anti-coagulation chemistry class 1 new drug SAR project organized and implemented by the National Center for New Drug Development Engineering Technology Research and Development and the signing ceremony for the transfer of achievements in the treatment of vascular dementia 5 class 5 new drugs Tianma benzyl alcohol glycoside tablets were held in Beijing.
According to reports, the first class of anticoagulant chemistry new drug SAR is the world's first dual-target anticoagulant drug independently developed by Sanofi, an internationally renowned pharmaceutical company, for the treatment of cardiovascular diseases. Studies and some toxicological tests. Through patent licensing, the National New Drug Development Engineering Technology Research Center will be responsible for the pharmacokinetics, drug safety, and clinical research of this variety in China for industrial development. On the same day, China and France jointly established an expert committee to officially start the research and development of the project in China.
Gastrodia benzyl alcohol glycoside tablets are a collaboration between the National New Drug Development Engineering Technology Research Center and the Chinese Academy of Medical Sciences to isolate a class of effective compounds from the Chinese herbal medicine Gastrodia, and then develop new drugs. The second five-year national "major new drug creation" major scientific and technological special support. At present, the variety has completed pre-clinical research and will be developed and produced by Beijing Xiehe Pharmaceutical No. 2 Factory in the future.
The National New Drug Development Engineering Technology Research Center is established by relying on the Institute of Medicine of the Chinese Academy of Sciences. It is the only new drug development engineering center established by the Ministry of Science and Technology in China.
non slip cutting board,non slip chopping board,flexible plastic cutting board
Rongxin New Material (Jiangsu) Co., Ltd. , https://www.rongxinxcljs.com